Semaglutide Proven to Lower Glycemia in Cardiovascular Patients without Diabetes

In a study involving 17,604 participants aged ≥45 years with BMI ≥27 kg/m² and preexisting cardiovascular disease but without diabetes (HbA1c <6.5%), subcutaneous semaglutide (2.4 mg weekly) or placebo was administered. Over a mean exposure of 152 weeks and a follow-up of 176 weeks, semaglutide significantly reduced HbA1c levels, favouring the treatment group. At week 156, a higher proportion of the semaglutide group achieved normoglycemia (69.5% vs 35.8%), and fewer progressed to diabetes. Weight reduction significantly mediated glycemic changes, with an 8.9% lower body weight plateau at 65 weeks. Semaglutide thus increased regression to normoglycemia and decreased progression to diabetes in this population.